Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Antiviral Mechanisms of Justicidin B and Tuberculatin from <i>Phyllanthus brasiliensis</i> against Oropouche Virus Infection.

ACS omega·2026
Same author

Immune landscape of COVID-19 recovery: Nucleocapsid as a major target of CD8+ T cell antiviral responses in convalescent HLA-A*02+ individuals from Brazil.

Journal of leukocyte biology·2026
Same author

Integrated reiterative pipeline for rapid epitope-based pan-alphavirus vaccines.

Science advances·2026
Same author

A Multi-Epitope Recombinant Vaccine Candidate Against Bovine Alphaherpesvirus 1 and 5 Elicits Robust Immune Responses in Mice and Rabbits.

Vaccines·2025
Same author

Discovery of benzyl carbamate inhibitors of coronavirus M<sup>pro</sup> enzymes from a legacy collection of cysteine protease inhibitors.

Journal of enzyme inhibition and medicinal chemistry·2025
Same author

Neuropsychomotor Development of Children Exposed to SARS-CoV-2 in Utero During COVID-19 Pandemic.

Biomedicines·2025

Related Experiment Video

Updated: Aug 23, 2025

Intranasal Administration of Recombinant Influenza Vaccines in Chimeric Mouse Models to Study Mucosal Immunity
10:39

Intranasal Administration of Recombinant Influenza Vaccines in Chimeric Mouse Models to Study Mucosal Immunity

Published on: June 25, 2015

12.7K

Developing a Feline Immunodeficiency Virus Subtype B Vaccine Prototype Using a Recombinant MVA Vector.

Luis A F Andrade1,2, Alice F Versiani3, Edel F Barbosa-Stancioli1

  • 1Laboratory of Basic and Applied Virology, Federal University of Minas Gerais, Belo Horizonte 31270-901, Brazil.

Vaccines
|October 27, 2022
PubMed
Summary

A new vaccine prototype targeting feline immunodeficiency virus subtype B (FIV-B) has been developed. Preclinical tests in mice show it effectively stimulates cellular and humoral immune responses, supporting further development for cat vaccination.

Keywords:
feline immunodeficiency virusmodified vaccinia virus Ankaravaccine

More Related Videos

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

9.6K
A Simple and Efficient Approach to Construct Mutant Vaccinia Virus Vectors
09:16

A Simple and Efficient Approach to Construct Mutant Vaccinia Virus Vectors

Published on: October 30, 2016

11.3K

Related Experiment Videos

Last Updated: Aug 23, 2025

Intranasal Administration of Recombinant Influenza Vaccines in Chimeric Mouse Models to Study Mucosal Immunity
10:39

Intranasal Administration of Recombinant Influenza Vaccines in Chimeric Mouse Models to Study Mucosal Immunity

Published on: June 25, 2015

12.7K
Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

9.6K
A Simple and Efficient Approach to Construct Mutant Vaccinia Virus Vectors
09:16

A Simple and Efficient Approach to Construct Mutant Vaccinia Virus Vectors

Published on: October 30, 2016

11.3K

Area of Science:

  • Veterinary Immunology
  • Virology
  • Vaccine Development

Background:

  • Feline immunodeficiency virus (FIV) is a global retrovirus causing severe immunosuppression in cats.
  • Current vaccines are ineffective against FIV subtype B (FIV-B), a prevalent strain worldwide.
  • There is a critical need for a FIV-B vaccine to protect domestic and wild felids.

Purpose of the Study:

  • To develop and evaluate a novel vaccine prototype against FIV-B.
  • To assess the immunogenicity and viability of a recombinant MVA-based vaccine candidate.

Main Methods:

  • Development of a modified vaccinia virus Ankara (MVA) vector expressing FIV-B envelope V1-V3 regions.
  • Preclinical testing in C57BL/6 mice using a prime-boost immunization protocol.
  • Evaluation of cellular (splenocyte proliferation, IFN-γ) and humoral (antibody) immune responses.
  • Assessment of vaccine viability after lyophilization and storage.

Main Results:

  • Immunization induced specific splenocyte proliferation upon stimulation with FIV-B peptides.
  • Evidence of cellular and humoral immunity activation, including IFN-γ production and specific antibodies.
  • The vaccine candidate demonstrated viability after lyophilization and storage, indicating potential for practical application.

Conclusions:

  • The MVA/FIV-B vaccine prototype successfully elicited specific immune responses in a preclinical mouse model.
  • The findings support further investigation and development of this vaccine for FIV-B prevention in cats.
  • This study represents a significant step towards a much-needed FIV-B vaccine.